1. Home
  2. TMCI vs CAPR Comparison

TMCI vs CAPR Comparison

Compare TMCI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMCI
  • CAPR
  • Stock Information
  • Founded
  • TMCI 2014
  • CAPR 2005
  • Country
  • TMCI United States
  • CAPR United States
  • Employees
  • TMCI N/A
  • CAPR N/A
  • Industry
  • TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TMCI Health Care
  • CAPR Health Care
  • Exchange
  • TMCI Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • TMCI 401.8M
  • CAPR 324.6M
  • IPO Year
  • TMCI 2021
  • CAPR N/A
  • Fundamental
  • Price
  • TMCI $6.03
  • CAPR $7.45
  • Analyst Decision
  • TMCI Hold
  • CAPR Strong Buy
  • Analyst Count
  • TMCI 5
  • CAPR 7
  • Target Price
  • TMCI $8.60
  • CAPR $24.71
  • AVG Volume (30 Days)
  • TMCI 292.8K
  • CAPR 1.4M
  • Earning Date
  • TMCI 11-04-2025
  • CAPR 11-12-2025
  • Dividend Yield
  • TMCI N/A
  • CAPR N/A
  • EPS Growth
  • TMCI N/A
  • CAPR N/A
  • EPS
  • TMCI N/A
  • CAPR N/A
  • Revenue
  • TMCI $213,751,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • TMCI $10.63
  • CAPR N/A
  • Revenue Next Year
  • TMCI $9.43
  • CAPR $7,894.07
  • P/E Ratio
  • TMCI N/A
  • CAPR N/A
  • Revenue Growth
  • TMCI 7.67
  • CAPR N/A
  • 52 Week Low
  • TMCI $4.54
  • CAPR $5.68
  • 52 Week High
  • TMCI $10.79
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • TMCI 29.93
  • CAPR 55.14
  • Support Level
  • TMCI $6.09
  • CAPR $7.11
  • Resistance Level
  • TMCI $6.52
  • CAPR $8.06
  • Average True Range (ATR)
  • TMCI 0.31
  • CAPR 0.52
  • MACD
  • TMCI -0.11
  • CAPR 0.20
  • Stochastic Oscillator
  • TMCI 0.00
  • CAPR 77.81

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: